Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Comment by dt_coreon Jul 14, 2023 10:09am
128 Views
Post# 35541034

RE:RE:New SAAS Contracts

RE:RE:New SAAS ContractsI've been wrong before too, which is why I always take any insights I hear with a grain of salt.

On another topic it's really interesting to run the number son what a potential WELL aquisition of THNK could look like it becomes obvious that it's a no-brainer deal for Well at $0.75, assuming THNK hits its EBITDA targets and not including any potential synergies and looking further down the road at 2024/2025 expected results than willingness to pay for WELL could be as high as $1.20 even if the deal was done 100% with Debt (would leave WELL with a Net Debt leverage ratio of ~3.0x on 2024 pro forma Adj. EBITDA and 2.7x 2025. All this to say that I suspect WELL must be circling THNK regarding an aquisition given how low the share price is today.
<< Previous
Bullboard Posts
Next >>